a<p>Mice were immunized with either LVS or ΔFTL_0883 at the indicated dose and then challenged with 100 CFU of Schu S4 i.t.</p>b<p>Significant difference p<0.005 by log rank test.</p
SW female mice were immunized and challenged as described in Fig 2. Vaccinated mice were treated wit...
<p>C57BL/6 mice (n = 5–10 per group) were immunized i.n. with 1×10<sup>6</sup> CFU of the <i>emrA1</...
<p>(A) Balb/c mice (n = 10/group) were infected intradermally with the indicated number of <i>F. tul...
<p>Mice (n = 5) were vaccinated i.d. (A) or i.n. (B) with 10-fold serial dilutions of Schu S4 Δ<i>pu...
<p>BALB/c mice (n = 4/group) were immunized ID with ∼10<sup>5</sup> CFU of FSC200 <i>ΔclpB</i> (circ...
<p>BALB/c mice were immunized ID with 10<sup>5</sup> CFU of LVS (square; n = 12) or FSC200<i>ΔclpB</...
<p>BALB/c mice (n = 5/group) were immunized with 10<sup>3</sup> (squares), 10<sup>5</sup> (circles),...
<p>Blue asterisk, significantly greater survival than control mice or mice immunized with LVS; green...
SW and C57BL/6 female mice were immunized i.n. with 1x103 CFU of attenuated Ft LVS sodB mutant. Mice...
<p>BALB/c mice (n = 4/group) were immunized ID with ∼10<sup>5</sup> CFU of FSC200 <i>ΔclpB</i> (circ...
<p>Mice were immunized with 50 μg of DNA vaccine intramuscularly via EP followed by two boosters wit...
<p><b>(A)</b> Mice were immunized with PBS, SL3261 (vector), or SL3261/p1C3 (vaccine) via the intran...
<p>Mice were immunized on day 0, 14 and 28 with DnaK+GPI, Tul4+GPI or DnaK+Tul4+GPI. Control groups ...
<p>Mice were either orally vaccinated with 10<sup>10</sup> BRD509 (⬜) or IV vaccinated with 10<sup>2...
<p>Groups of ten BALB/c mice (3-week-old) were vaccinated with 5×10<sup>4</sup> PFU MVTT1, MVTT2 or ...
SW female mice were immunized and challenged as described in Fig 2. Vaccinated mice were treated wit...
<p>C57BL/6 mice (n = 5–10 per group) were immunized i.n. with 1×10<sup>6</sup> CFU of the <i>emrA1</...
<p>(A) Balb/c mice (n = 10/group) were infected intradermally with the indicated number of <i>F. tul...
<p>Mice (n = 5) were vaccinated i.d. (A) or i.n. (B) with 10-fold serial dilutions of Schu S4 Δ<i>pu...
<p>BALB/c mice (n = 4/group) were immunized ID with ∼10<sup>5</sup> CFU of FSC200 <i>ΔclpB</i> (circ...
<p>BALB/c mice were immunized ID with 10<sup>5</sup> CFU of LVS (square; n = 12) or FSC200<i>ΔclpB</...
<p>BALB/c mice (n = 5/group) were immunized with 10<sup>3</sup> (squares), 10<sup>5</sup> (circles),...
<p>Blue asterisk, significantly greater survival than control mice or mice immunized with LVS; green...
SW and C57BL/6 female mice were immunized i.n. with 1x103 CFU of attenuated Ft LVS sodB mutant. Mice...
<p>BALB/c mice (n = 4/group) were immunized ID with ∼10<sup>5</sup> CFU of FSC200 <i>ΔclpB</i> (circ...
<p>Mice were immunized with 50 μg of DNA vaccine intramuscularly via EP followed by two boosters wit...
<p><b>(A)</b> Mice were immunized with PBS, SL3261 (vector), or SL3261/p1C3 (vaccine) via the intran...
<p>Mice were immunized on day 0, 14 and 28 with DnaK+GPI, Tul4+GPI or DnaK+Tul4+GPI. Control groups ...
<p>Mice were either orally vaccinated with 10<sup>10</sup> BRD509 (⬜) or IV vaccinated with 10<sup>2...
<p>Groups of ten BALB/c mice (3-week-old) were vaccinated with 5×10<sup>4</sup> PFU MVTT1, MVTT2 or ...
SW female mice were immunized and challenged as described in Fig 2. Vaccinated mice were treated wit...
<p>C57BL/6 mice (n = 5–10 per group) were immunized i.n. with 1×10<sup>6</sup> CFU of the <i>emrA1</...
<p>(A) Balb/c mice (n = 10/group) were infected intradermally with the indicated number of <i>F. tul...